메뉴 건너뛰기




Volumn 5, Issue 2, 2010, Pages 119-129

Targeted therapies for non-clear renal cell carcinoma

Author keywords

Chromophobe; Collecting duct; Kidney cancer; Non clear cell; Papillary; Renal cell carcinoma; Targeted therapy

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CISPLATIN; ERLOTINIB; EVEROLIMUS; FUMARATE HYDRATASE; GEMCITABINE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; XL 880;

EID: 77958012311     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0148-3     Document Type: Review
Times cited : (27)

References (84)
  • 3
    • 45549090890 scopus 로고    scopus 로고
    • Genetic basis for kidney cancer: Opportunity for disease-specific approaches to therapy
    • Pfaffenroth EC, Linehan WM (2008) Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther 8 (6):779-790
    • (2008) Expert Opin. Biol. Ther. , vol.8 , Issue.6 , pp. 779-790
    • Pfaffenroth, E.C.1    Linehan, W.M.2
  • 4
  • 5
    • 0242608613 scopus 로고    scopus 로고
    • The genetic basis of cancer of the kidney
    • Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170 (6 Pt 1):2163-2172
    • (2003) J. Urol. , vol.170 , Issue.1-6 PART , pp. 2163-2172
    • Linehan, W.M.1    Walther, M.M.2    Zbar, B.3
  • 7
    • 67650327598 scopus 로고    scopus 로고
    • Metastatic renal cell carcinoma: Many treatment options, one patient
    • Rini BI (2009) Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 27 (19):3225-3234
    • (2009) J. Clin. Oncol. , vol.27 , Issue.19 , pp. 3225-3234
    • Rini, B.I.1
  • 8
    • 62849128369 scopus 로고    scopus 로고
    • Renal cell carcinoma
    • Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373 (9669):1119-1132
    • (2009) Lancet , vol.373 , Issue.9669 , pp. 1119-1132
    • Rini, B.I.1    Campbell, S.C.2    Escudier, B.3
  • 9
    • 70350571201 scopus 로고    scopus 로고
    • Metastatic renal cell carcinoma: Recent advances in the targeted therapy era
    • Di Lorenzo G, Autorino R, Sternberg CN (2009) Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 56 (6):959-971
    • (2009) Eur. Urol. , vol.56 , Issue.6 , pp. 959-971
    • Di Lorenzo, G.1    Autorino, R.2    Sternberg, C.N.3
  • 10
  • 18
    • 34248661866 scopus 로고    scopus 로고
    • Renal cell carcinoma: Current status and emerging therapies
    • Nelson EC, Evans CP, Lara PN Jr (2007) Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 33 (3):299-313
    • (2007) Cancer Treat Rev. , vol.33 , Issue.3 , pp. 299-313
    • Nelson, E.C.1    Evans, C.P.2    Lara Jr., P.N.3
  • 19
    • 84875618931 scopus 로고    scopus 로고
    • Race determines histologic subtypes and stage of RCC: An analysis of the seer database
    • Abstract 314
    • Chung PH, Linehan WM, Bratslavsky G (2010) Race determines histologic subtypes and stage of RCC: an analysis of the seer database. 2010 Genitourinary Cancers Symposium: Abstract 314
    • (2010) 2010 Genitourinary Cancers Symposium
    • Chung, P.H.1    Linehan, W.M.2    Bratslavsky, G.3
  • 20
    • 77953536522 scopus 로고    scopus 로고
    • Kinase targets in renalcell carcinomas: Reassessing the old and discovering the new
    • Furge KA, Mackeigan JP, Teh BT (2010) Kinase targets in renalcell carcinomas: reassessing the old and discovering the new. Lancet Oncol 11 (6):571-578
    • (2010) Lancet Oncol. , vol.11 , Issue.6 , pp. 571-578
    • Furge, K.A.1    Mackeigan, J.P.2    Teh, B.T.3
  • 24
    • 0032514365 scopus 로고    scopus 로고
    • Duplication and overexpression of the mutant allele of the met proto-oncogene in multiple hereditary papillary renal cell tumours
    • Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F, Kovacs G (1998) Duplication and overexpression of the mutant allele of the met proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 17 (6):733-739
    • (1998) Oncogene , vol.17 , Issue.6 , pp. 733-739
    • Fischer, J.1    Palmedo, G.2    Von Knobloch, R.3    Bugert, P.4    Prayer-Galetti, T.5    Pagano, F.6    Kovacs, G.7
  • 26
    • 33749449442 scopus 로고    scopus 로고
    • Genetic basis of cancer of the kidney
    • Sudarshan S, Linehan WM (2006) Genetic basis of cancer of the kidney. Semin Oncol 33 (5):544-551
    • (2006) Semin Oncol. , vol.33 , Issue.5 , pp. 544-551
    • Sudarshan, S.1    Linehan, W.M.2
  • 31
    • 34748836454 scopus 로고    scopus 로고
    • The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome
    • Merino MJ, Torres-Cabala C, Pinto P, Linehan WM (2007) The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31 (10):1578-1585
    • (2007) Am. J. Surg. Pathol. , vol.31 , Issue.10 , pp. 1578-1585
    • Merino, M.J.1    Torres-Cabala, C.2    Pinto, P.3    Linehan, W.M.4
  • 33
    • 0037407573 scopus 로고    scopus 로고
    • Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma
    • DOI 10.1097/00000478-200305000-00005
    • Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27 (5):612-624 (Pubitemid 36514472)
    • (2003) American Journal of Surgical Pathology , vol.27 , Issue.5 , pp. 612-624
    • Cheville, J.C.1    Lohse, C.M.2    Zincke, H.3    Weaver, A.L.4    Blute, M.L.5
  • 35
    • 41149090291 scopus 로고    scopus 로고
    • Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma
    • Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG (2008) Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer 112 (7):1480-1488
    • (2008) Cancer , vol.112 , Issue.7 , pp. 1480-1488
    • Margulis, V.1    Tamboli, P.2    Matin, S.F.3    Swanson, D.A.4    Wood, C.G.5
  • 41
    • 0036569472 scopus 로고    scopus 로고
    • Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
    • Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 (9):2376-2381
    • (2002) J. Clin. Oncol. , vol.20 , Issue.9 , pp. 2376-2381
    • Motzer, R.J.1    Bacik, J.2    Mariani, T.3    Russo, P.4    Mazumdar, M.5    Reuter, V.6
  • 43
    • 79952707246 scopus 로고    scopus 로고
    • Sunitinib in papillary renal cell carcinoma (prcc): Results from a single-arm phase ii study
    • abstr 4604
    • Plimack ER, Jonasch E, Bekele BN, Qiao W, Tamboli P, Ng CS, Tannir NM (2010) Sunitinib in papillary renal cell carcinoma (prcc): results from a single-arm phase ii study. J Clin Oncol 28:15s, suppl; abstr 4604
    • (2010) J. Clin. Oncol. , vol.28 , Issue.SUPPL.
    • Plimack, E.R.1    Jonasch, E.2    Bekele, B.N.3    Qiao, W.4    Tamboli, P.5    Ng, C.S.6    Tannir, N.M.7
  • 44
    • 77957984795 scopus 로고    scopus 로고
    • First-line sunitinib in type I and II papillary renal cell carcinoma (prcc): Supap, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase Trials (GEP)
    • Ravaud A, Oudard S, Gravis-Mescam G, Sevin E, Zanetta S, Theodore C, de Fromont M, Mahier-Ait Oukhatar C, Chene G, Escudier B (2009) First-line sunitinib in type I and II papillary renal cell carcinoma (prcc): Supap, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase Trials (GEP). J Clin Oncol 27 (15 S): 5146
    • (2009) J. Clin. Oncol. , vol.27 , Issue.15 S , pp. 5146
    • Ravaud, A.1    Oudard, S.2    Gravis-Mescam, G.3    Sevin, E.4    Zanetta, S.5    Theodore, C.6    De Fromont, M.7    Mahier-Ait Oukhatar, C.8    Chene, G.9    Escudier, B.10
  • 47
    • 71049154727 scopus 로고    scopus 로고
    • A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC)
    • post-meeting addition:Abstract 5103
    • Srinivasan R, Linehan WM, Vaishampayan U, Logan T, Shankar SM, Sherman LJ, Liu Y, Choueiri TK (2009) A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 27 (15S (post-meeting addition)):Abstract 5103
    • (2009) J. Clin. Oncol. , vol.27
    • Srinivasan, R.1    Linehan, W.M.2    Vaishampayan, U.3    Logan, T.4    Shankar, S.M.5    Sherman, L.J.6    Liu, Y.7    Choueiri, T.K.8
  • 58
    • 0022998843 scopus 로고
    • Collecting duct carcinoma of the kidney
    • Fleming S, Lewi HJ (1986) Collecting duct carcinoma of the kidney. Histopathology 10 (11):1131-1141
    • (1986) Histopathology , vol.10 , Issue.11 , pp. 1131-1141
    • Fleming, S.1    Lewi, H.J.2
  • 59
    • 67651233821 scopus 로고    scopus 로고
    • Non-clear cell renal cancer: Features and medical management
    • Heng DY, Choueiri TK (2009) Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw 7 (6):659-665
    • (2009) J. Natl. Compr Canc Netw , vol.7 , Issue.6 , pp. 659-665
    • Heng, D.Y.1    Choueiri, T.K.2
  • 60
    • 34147107084 scopus 로고    scopus 로고
    • Prospective multicenter phase ii study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: Results of a GETUG (Groupe d'etudes des tumeurs uro-genitales) study
    • Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, Banu A, Duclos B, Rolland F, Escudier B, Arakelyan N, Culine S (2007) Prospective multicenter phase ii study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'etudes des tumeurs uro-genitales) study. J Urol 177 (5):1698-1702
    • (2007) J. Urol. , vol.177 , Issue.5 , pp. 1698-1702
    • Oudard, S.1    Banu, E.2    Vieillefond, A.3    Fournier, L.4    Priou, F.5    Medioni, J.6    Banu, A.7    Duclos, B.8    Rolland, F.9    Escudier, B.10    Arakelyan, N.11    Culine, S.12
  • 62
    • 1542327748 scopus 로고    scopus 로고
    • Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
    • Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (3):1071-1076
    • (2004) J. Urol. , vol.171 , Issue.3 , pp. 1071-1076
    • Flanigan, R.C.1    Mickisch, G.2    Sylvester, R.3    Tangen, C.4    Van Poppel, H.5    Crawford, E.D.6
  • 63
    • 0035934596 scopus 로고    scopus 로고
    • Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renalcell carcinoma: A randomised trial
    • Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renalcell carcinoma: a randomised trial. Lancet 358 (9286):966-970
    • (2001) Lancet , vol.358 , Issue.9286 , pp. 966-970
    • Mickisch, G.H.1    Garin, A.2    Van Poppel, H.3    De Prijck, L.4    Sylvester, R.5
  • 64
    • 0025041298 scopus 로고
    • Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells
    • discussion 617-618
    • Robertson CN, Linehan WM, Pass HI, Gomella LG, Haas GP, Berman A, Merino M, Rosenberg SA (1990) Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 144 (3):614-617, discussion 617-618
    • (1990) J. Urol. , vol.144 , Issue.3 , pp. 614-617
    • Robertson, C.N.1    Linehan, W.M.2    Pass, H.I.3    Gomella, L.G.4    Haas, G.P.5    Berman, A.6    Merino, M.7    Rosenberg, S.A.8
  • 66
    • 0032883614 scopus 로고    scopus 로고
    • Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place
    • Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC (1999) Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 162 (1):43-45
    • (1999) J. Urol. , vol.162 , Issue.1 , pp. 43-45
    • Wagner, J.R.1    Walther, M.M.2    Linehan, W.M.3    White, D.E.4    Rosenberg, S.A.5    Yang, J.C.6
  • 67
    • 34248369806 scopus 로고    scopus 로고
    • The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy
    • Rini BI, Campbell SC (2007) The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 177 (6):1978-1984
    • (2007) J. Urol. , vol.177 , Issue.6 , pp. 1978-1984
    • Rini, B.I.1    Campbell, S.C.2
  • 68
    • 16244379522 scopus 로고    scopus 로고
    • VEGF-targeted therapy in metastatic renal cell carcinoma
    • Rini BI (2005) VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist 10 (3):191-197
    • (2005) Oncologist , vol.10 , Issue.3 , pp. 191-197
    • Rini, B.I.1
  • 69
    • 77949451507 scopus 로고    scopus 로고
    • Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy
    • Abel EJ, Wood CG (2009) Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol 6 (7):375-383
    • (2009) Nat. Rev. Urol. , vol.6 , Issue.7 , pp. 375-383
    • Abel, E.J.1    Wood, C.G.2
  • 73
    • 72549101585 scopus 로고    scopus 로고
    • Neoadjuvant treatment of renal cell carcinoma
    • Rathmell WK, Pruthi R, Wallen E (2010) Neoadjuvant treatment of renal cell carcinoma. Urol Oncol 28 (1):69-73
    • (2010) Urol. Oncol. , vol.28 , Issue.1 , pp. 69-73
    • Rathmell, W.K.1    Pruthi, R.2    Wallen, E.3
  • 75
    • 58149145722 scopus 로고    scopus 로고
    • Pre-surgical targeted molecular therapy in renal cell carcinoma
    • Margulis V, Wood CG (2009) Pre-surgical targeted molecular therapy in renal cell carcinoma. BJU Int 103 (2):150-153
    • (2009) BJU Int. , vol.103 , Issue.2 , pp. 150-153
    • Margulis, V.1    Wood, C.G.2
  • 76
    • 0038514165 scopus 로고    scopus 로고
    • Phase III study of interferon alfa-nl as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial
    • Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D (2003) Phase III study of interferon alfa-nl as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21 (7):1214-1222
    • (2003) J. Clin. Oncol. , vol.21 , Issue.7 , pp. 1214-1222
    • Messing, E.M.1    Manola, J.2    Wilding, G.3    Propert, K.4    Fleischmann, J.5    Crawford, E.D.6    Pontes, J.E.7    Hahn, R.8    Trump, D.9
  • 77
    • 0035863285 scopus 로고    scopus 로고
    • Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study
    • Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19 (2):425-431
    • (2001) J. Clin. Oncol. , vol.19 , Issue.2 , pp. 425-431
    • Pizzocaro, G.1    Piva, L.2    Colavita, M.3    Ferri, S.4    Artusi, R.5    Boracchi, P.6    Parmiani, G.7    Marubini, E.8
  • 78
    • 20144388609 scopus 로고    scopus 로고
    • Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
    • DOI 10.1038/sj.bjc.6602443
    • Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Woltjen HH, Jentsch H, Wieland W, Wandert T, Reitz M (2005) Adjuvant treatment with interleukin-2-and interferon-alpha2A-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92 (5):843-846 (Pubitemid 40462628)
    • (2005) British Journal of Cancer , vol.92 , Issue.5 , pp. 843-846
    • Atzpodien, J.1    Schmitt, E.2    Gertenbach, U.3    Fornara, P.4    Heynemann, H.5    Maskow, A.6    Ecke, M.7    Woltjen, H.H.8    Jentsch, H.9    Wieland, W.10    Wandert, T.11    Reitz, M.12
  • 79
    • 77958022573 scopus 로고    scopus 로고
    • NIH, Available from:, cited June 27, 2010
    • NIH (2010) Clinical trials basic search. Available from: http://clinicaltrials.gov/ct2/search [cited June 27, 2010]
    • (2010) Clinical Trials Basic Search
  • 80
    • 54549120308 scopus 로고    scopus 로고
    • Cytoreductive nephrectomy in metastatic renal cell carcinoma
    • Margulis V, Matin SF, Wood CG (2008) Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr Opin Urol 18 (5):474-480
    • (2008) Curr. Opin. Urol. , vol.18 , Issue.5 , pp. 474-480
    • Margulis, V.1    Matin, S.F.2    Wood, C.G.3
  • 81
    • 44649192971 scopus 로고    scopus 로고
    • Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
    • Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG (2008) Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180 (1):94-98
    • (2008) J. Urol. , vol.180 , Issue.1 , pp. 94-98
    • Margulis, V.1    Matin, S.F.2    Tannir, N.3    Tamboli, P.4    Swanson, D.A.5    Jonasch, E.6    Wood, C.G.7
  • 82
    • 14544302234 scopus 로고    scopus 로고
    • Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported community clinical oncology program
    • Buchanan DR, O'Mara AM, Kelaghan JW, Minasian LM (2005) Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported community clinical oncology program. J Clin Oncol 23 (3):591-598
    • (2005) J. Clin. Oncol. , vol.23 , Issue.3 , pp. 591-598
    • Buchanan, D.R.1    O'Mara, A.M.2    Kelaghan, J.W.3    Minasian, L.M.4
  • 83
    • 67651233820 scopus 로고    scopus 로고
    • New treatments for renal cell carcinoma: Targeted therapies
    • Saylor PJ, Michaelson MD (2009) New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw 7 (6):645-656
    • (2009) J. Natl. Compr Canc Netw , vol.7 , Issue.6 , pp. 645-656
    • Saylor, P.J.1    Michaelson, M.D.2
  • 84
    • 77149137763 scopus 로고    scopus 로고
    • A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia
    • Liu J, Mittendorf T, von der Schulenburg JM (2010) A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest 28 (3):312-322
    • (2010) Cancer Invest. , vol.28 , Issue.3 , pp. 312-322
    • Liu, J.1    Mittendorf, T.2    Von Der Schulenburg, J.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.